Dr Tim Robinson

I am an Associate Professor in Breast Oncology at the University of Bristol and an Honorary Consultant Medical Oncologist at Bristol NHS Foundation Trust specialising in breast cancer. I practice in all areas of breast oncology but have a special interest in younger women with breast cancer, management of the side effects of treatment, antibody drug conjugates, including Her2 low disease, molecular testing and in triple negative breast cancer. I am passionate about improving patient care and helping patients decide the best individual treatment for them and I always spend time trying to go above and beyond for patients with appointments never shorter than 30 minutes for follow ups or 60 minutes for new patients or second opinions. I regularly give talks for Breast Cancer Now for women with breast cancer to help them understand treatment options for both metastatic breast cancer and TNBC.

I completed my medical oncology clinical and academic training in Bristol and undertook a Cancer Research UK Clinical Fellowship leading to being awarded a PhD from Cardiff University examining the role of breast cancer stem cells in chemo-resistance and exploring novel therapeutic strategies. I also undertook a postgraduate diploma in oncology from the Institute of Cancer Research University of London. I was the recipient of a Coltmans Scholar Award from the San Antonio Breast Cancer Symposium (SABCS), the worlds largest breast cancer meeting, for work on the gut microbiome and breast cancer, and have multiple peer-reviewed publications. I have presented widely at national and international conferences - including being on the faculty at SABCS 2026 as part of the TNBC educational track.

I am heavily involved in clinical trials as a principal investigator in Bristol and global chief investigator. This includes global chief investigator roles in 2 clinical studies for metastatic breast cancer and I have trials in both the NHS and private sector.  I am a member of national collaborative research groups and was appointed to the National Cancer Institute Breast Cancer Precision Medicine Working group in 2022 and I am member of the NICE expert panel of breast oncologists for the breast cancer guideline committee.

I strive to provide personalised care using up-to-date pragmatic evidenced-based medicine.